Alzheimer's Opportunity CytoDyn has initiated a Phase 2a study of leronlimab for Alzheimer's disease in collaboration with Weill Cornell Medicine, indicating a potential foothold in the neurodegenerative space. Sales outreach can target neurology clinics, research networks, and AD-focused patient advocacy groups to explore partnership opportunities, biomarkers, and trial recruitment collaborations.

Oncology Expansion Recent activity includes expanded access for triple-negative breast cancer and data presentations in metastatic colorectal cancer, highlighting leronlimab’s applicability across aggressive cancers. BD efforts should focus on oncology centers, academic networks, and pharma/biotech co-development interests for combination therapies and later-stage trials.

Clinical Development Momentum Multiple Phase 2 studies and ongoing enrollment for colorectal cancer demonstrate ongoing clinical momentum. Leverage these trials to engage KOLs, contract research organizations, and hospital systems for investigator-initiated studies, site expansion, and potential supply agreements.

Strategic Collaborations Collaborations with prestigious institutions like Weill Cornell and active investor communications signal a growth trajectory. Target large pharma/biotech partners for strategic alliances, co-development deals, or licensing discussions around leronlimab’s CCR5 mechanism across indications.

Financing and Visibility The company reports mid-range revenue and ongoing funding, plus investor events and webcasts. This suggests opportunities for financing-aligned partnerships, strategic sponsorships, and joint marketing days with investor relations to accelerate clinical programs and clinical trial recruitment.